ReviewFrontiers in molecular neuroscience2018
Into the Fourth Dimension: Dysregulation of Genome Architecture in Aging and Alzheimer's Disease.
Review in Frontiers in molecular neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Spatially resolved mapping of histones reveals selective neuronal response in Rett syndrome.The FEBS journal · 2026Article
- Tau-induced increase in promoter-proximal RNA polymerase II pausing is linked to suppressed expression of long neuronal genes in aFrontiers in aging neuroscience · 2026Article
- DNA methylation patterns contribute to changes of cellular differentiation pathways in leukocytes with LOY from patients with Alzheimer´s disease.Cellular and molecular life sciences : CMLS · 2025Article
- Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism.bioRxiv : the preprint server for biology · 2024Article
- Deep learning approaches for noncoding variant prioritization in neurodegenerative diseases.Frontiers in aging neuroscience · 2022Review
- Acute myocardial infarction induces remodeling of the murine superior cervical ganglia and the carotid body.Frontiers in cardiovascular medicine · 2022Article
- Three-dimensional virtual histology of the human hippocampus based on phase-contrast computed tomography.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Nuclear dynamics and stress responses in Alzheimer's disease.Molecular neurodegeneration · 2021Review
- Tau Oligomers Neurotoxicity.Life (Basel, Switzerland) · 2021Review
- Influence ofAging and disease · 2020Review
- Perinuclear Lamin A and Nucleoplasmic Lamin B2 Characterize Two Types of Hippocampal Neurons through Alzheimer's Disease Progression.International journal of molecular sciences · 2020Article
- Cellular Senescence in Neurodegenerative Diseases.Frontiers in cellular neuroscience · 2020Review
- The transcript expression levels of HNRNPM, HNRNPA0 and AKAP17A splicing factors may be predictively associated with ageing phenotypes in human peripheral blood.Biogerontology · 2019Article
- Aging-induced Akt activation involves in aging-related pathologies and Aβ-induced toxicity.Aging cell · 2019Article
- Article
- The X Files: "The Mystery of X Chromosome Instability in Alzheimer's Disease".Frontiers in genetics · 2019Review
- Genome-wide identification of genic and intergenic neuronal DNA regions bound by Tau protein under physiological and stress conditions.Nucleic acids research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by synapse dysfunction and cognitive impairment. Understanding the development and progression of AD is challenging, as the disease is highly complex and multifactorial. Both environmental and genetic factors play a role in AD pathogenesis, highlighted by observations of complex DNA modifications at the single gene level, and by new evidence that also implicates changes in genome architecture in AD patients. The four-dimensional structure of chromatin in space and time is essential for context-dependent regulation of gene expression in post-mitotic neurons. Dysregulation of epigenetic processes have been observed in the aging brain and in patients with AD, though there is not yet agreement on the impact of these changes on transcription. New evidence shows that proteins involved in genome organization have altered expression and localization in the AD brain, suggesting that the genomic landscape may play a critical role in the development of AD. This review discusses the role of the chromatin organizers and epigenetic modifiers in post-mitotic cells, the aging brain, and in the development and progression of AD. How these new insights can be used to help determine disease risk and inform treatment strategies will also be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.